In 7 of 11 CVID patients, reactive CD4+ T cells against at least one spike peptide pool of SARS-CoV-2 were detectable and in 4 of these 7 also against HCoV-229 and/or –OC43, but none against NCAP (Figure 2A). Here, CD4 is linked to common variable immunodeficiency.